Back to News & Events
Funding Opportunity: Long Island Bioscience Hub REACH
August 26, 2019
The Center for Biotechnology, on behalf of Long Island Bioscience Hub (LIBH), is pleased to announce the opening of the 8th round of the LIBH Technology Development RFP.
Two specific funding programs have been designed to help faculty, physicians, surgeons, medical fellows, and post-docs develop their academic innovations toward commercial goals. The RFP is and forms for the funding programs can be found on the Center for Biotechnology website here.
Those interested in applying are strongly encouraged to discuss the proposal with:
Anton Xavier (anton.xavier@stonybrook.edu)
William Hanes (william.hanes@stonybrook.edu)
Heather Bielski Lawler (heather.bielski@stonybrook.edu)
Johnna St Clair (johnna.stclair@stonybrook.edu)
They are happy to introduce this Technology Development program and provide support to address unfamiliar questions in the application.
Deadline for submission is Sep 13th, 2019. All proposal should be submitted through the online portal HERE. Please note an approval from your Sponsored Programs Office is NOT required prior to the submission but will be required if the project is selected for NIH secondary review. Eligible applicants will be notified if their application is selected to move forward.
The Center for Biotechnology, in collaboration with Stony Brook University, Cold Spring Harbor Laboratory, Brookhaven National Laboratory, and the Feinstein Institute for Medical Research, formed the LIBH. A principal goal of the LIBH is to foster the development of therapeutics, diagnostics, devices and research tools emerging from within the four partner institutions that address diseases within the mission of NIH. The LIBH is supported by the National Institutes of Health REACH initiative (Research Evaluation and Commercialization Hub), our four partner institutions, The Research Foundation for SUNY, and Empire State Development.
Related Stories
WP_Query Object
(
[query] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
)
[query_vars] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
[order] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts
WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
ORDER BY RAND()
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 4439
[post_author] => 3
[post_date] => 2024-07-30 15:29:07
[post_date_gmt] => 2024-07-30 19:29:07
[post_content] =>
CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.
The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.
Read more about IAMBIC and their recent funding here.
[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant
[post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-19 10:50:15
[post_modified_gmt] => 2024-11-19 15:50:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4439
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 2878
[post_author] => 1
[post_date] => 2017-11-21 14:36:09
[post_date_gmt] => 2017-11-21 14:36:09
[post_content] => The proposal submission deadline for the SUNY Technology Accelerator Fund Class of 2018 is February 16, 2018.
Faculty, staff, and students from all disciplines and campuses are encouraged to submit proposals for the SUNY Technology Accelerator Fund Class of 2018 funding. The deadline for submitting proposals is February 16, 2018. See TAF Class of 2018 Application and Administrative Guidelines.
The SUNY Technology Accelerator Fund (“TAF”) provides funding to support the advancement of SUNY innovations from the lab to the marketplace. Since its launch in 2011, the TAF has successfully advanced the commercial readiness of a number of SUNY-developed innovations. In most cases, SUNY innovations developed through sponsored research lack critical proof-of-concept data that is needed to attract investment by potential licensees or investors. TAF support targets the critical milestones needed to demonstrate that an innovation is worthy of external investment. TAF’s strategic objective is to facilitate the commercialization of SUNY-developed innovations for the public benefit in an expeditious and effective manner. The aim is to identify opportunities where small investments will provide significant impacts on making SUNY innovations available to the public. Different from fundamental research, TAF investments support proof-of-concept and technology development projects to validate the commercial feasibility of SUNY technology. The goal is to facilitate the translation of SUNY technology into marketable products and/or services by enhancing strategic academic-industry partnerships and building new entrepreneurial
Please be advised that all proposals require the review and participation of your campus administration prior to submission. To be certain that you adhere to any local proposal submission deadlines, we urge you to immediately contact your technology transfer office and/or office of sponsored programs if you are interested in applying for TAF Class of 2018 funding.
Questions? Please send any questions to TAF@rfsuny.org. All questions and answers will be posted to www.rfsuny.org/taf.
[post_title] => Funding Opportunity: SUNY Technology Accelerator Fund Accepting Proposals
[post_excerpt] => Proposal Deadline for the SUNY Technology Accelerator Fund Class of 2018 is February 16, 2018! SUNY Technology Accelerator Fund (“TAF”) provides funding to support the advancement of SUNY innovations from the lab to the marketplace.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => funding-opportunity-suny-technology-accelerator-fund-accepting-proposals-2
[to_ping] =>
[pinged] =>
[post_modified] => 2018-01-23 14:38:56
[post_modified_gmt] => 2018-01-23 14:38:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2878
[menu_order] => 135
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 2683
[post_author] => 3
[post_date] => 2017-05-05 19:56:20
[post_date_gmt] => 2017-05-05 19:56:20
[post_content] => On Thursday May 4, 2017 Center for Biotechnology Director Dr. Clinton Rubin was fortunate to testify at a joint congressional hearing on "Improving the Small Business Innovation Research and Small Business Technology Transfer Programs”. Dr. Rubin was present to discuss the NIH-REACH Program - which is the program that supported the creation of the Long Island Bioscience Hub.
Dr. Rubin spoke about the importance of initiatives like REACH which promote the development of “Phase 0” proof-of concept centers embedded within university communities. The activities of these centers are critical in promoting under-realized innovations out of academic labs and into the hands of patients as Universities often face significant challenges when it comes to commercializing translational research. He talk about the fact that in a very short amount of time, the three hubs created by the REACH program have already seen major impacts at our institution, fostering new intellectual property, increasing credibility with the investor community, promoting a shift in the academic culture, attracting new licensing opportunities, and most importantly, catalyzing the formation of new companies – some of which have successfully secured SBIR funding.
Programs like REACH fuel the growth of the small business community around university centers, and drives science towards successful new treatments for disease.
The committee hearing is available to view at this link. Dr. Rubin’s comments begin at 2:53:06
[caption id="attachment_2684" align="alignleft" width="300"]
CFB Director Clint Rubin and Director of Operations Diane Fabel at a joint congressional hearing on May 4, 2017.[/caption]
[post_title] => CFB Director Testifies Before Joint Congressional Hearing
[post_excerpt] => Dr. Rubin Dr. Clinton Rubin discussed the NIH-REACH Program and the Long island Bioscience Hub at a recent joint congressional hearing on "Improving the Small Business Innovation Research and Small Business Technology Transfer Programs”.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => cfb-director-testifies-before-joint-congressional-hearing
[to_ping] =>
[pinged] =>
[post_modified] => 2017-05-19 18:29:37
[post_modified_gmt] => 2017-05-19 18:29:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2683
[menu_order] => 148
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 1932
[post_author] => 1
[post_date] => 2015-12-30 21:39:54
[post_date_gmt] => 2015-12-30 21:39:54
[post_content] => DepYmed, a joint venture of Cold Spring Harbor Laboratory and New York City-based biotech Ohr Pharmaceutical led by Andreas Grill, has received $100,000 from Accelerate Long Island and the Long Island Emerging Technologies Fund. Andreas Grill has served as a BioEntrepreneur-in-Residence for the center for Biotechnology and DepYmed is developing a new drug called Trodusquemine that it hopes will one day treat HER2-positive breast cancer, an aggressive form of the disease. Read more about the company and the investment from Accelerate and LIETF here.
[post_title] => Depymed Received $100k from Accelerate Long Island & LIETF
[post_excerpt] => DepYmed has received $100,000 from Accelerate Long Island and the Long Island Emerging Technologies Fund.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => depymed-received-100k-from-accelerate-long-island-lietf
[to_ping] =>
[pinged] =>
[post_modified] => 2016-03-29 20:28:36
[post_modified_gmt] => 2016-03-29 20:28:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/new/?p=1932
[menu_order] => 193
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4439
[post_author] => 3
[post_date] => 2024-07-30 15:29:07
[post_date_gmt] => 2024-07-30 19:29:07
[post_content] =>
CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.
The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.
Read more about IAMBIC and their recent funding here.
[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant
[post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-19 10:50:15
[post_modified_gmt] => 2024-11-19 15:50:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4439
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 261
[max_num_pages] => 87
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] =>
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] => 1
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] =>
[query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)
July 30, 2024
More Information
November 21, 2017
More Information
May 5, 2017
More Information
December 30, 2015
More Information
